MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis

I Tchetverikov, L S Lohmander, N Verzijl, T W J Huizinga, J M TeKoppele, R Hanemaaijer, J DeGroot, I Tchetverikov, L S Lohmander, N Verzijl, T W J Huizinga, J M TeKoppele, R Hanemaaijer, J DeGroot

Abstract

Objective: To determine protein and activity levels of matrix metalloproteinases 1 and 3 (MMP-1 and MMP-3) in synovial fluid of patients with knee joint injury, primary osteoarthritis, and acute pyrophosphate arthritis (pseudogout).

Methods: Measurements were done on knee synovial fluid obtained in a cross sectional study of cases of injury (n = 283), osteoarthritis (n = 105), and pseudogout (n = 65), and in healthy controls (n = 35). Activity of MMP-1 and MMP-3 in alpha(2) macroglobulin complexes was measured using specific low molecular weight fluorogenic substrates. ProMMP-1, proMMP-3, and TIMP-1 (tissue inhibitor of metalloproteinase 1) were quantified by immunoassay.

Results: Mean levels of proMMP-1, proMMP-3, and TIMP-1 were increased in injury, osteoarthritis, and pseudogout compared with controls. MMP-1 activity was increased in pseudogout and injury groups over control levels, whereas MMP-3 activity was increased only in the pseudogout group. The increase in MMP-1 activity coincided with a decrease in TIMP-1 levels in the injury group.

Conclusions: Patients with joint injury have a persistent increase in proMMP-1 and proMMP-3 in synovial fluid and an increase in activated MMPs, which are not inhibited by TIMP. The differences in activation and inhibition patterns between the study groups are consistent with disease specific patterns of MMP activation and/or inhibition in joint pathology.

Figures

Figure 1
Figure 1
ProMMP-1 concentration (A), MMP-1 activity (B), TIMP-1 concentration (C), proMMP-3 concentration (D), and MMP-3 activity (E) in synovial fluid v time after injury (values are medians with standard errors). The whole group was divided into "time windows" based on time of sampling after injury: 0–0.6 weeks (n = 44), 0.6–2 weeks (n = 58), 2–17 weeks (n = 45), 17–57 weeks (n = 50), 58–170 weeks (n = 47), 180–1500 weeks (n = 39). Time of sampling after injury is reported on a logarithmic scale. Dashed line represents corresponding values in control groups. MMP, matrix metalloproteinase; proMMP, pro-matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinases.
Figure 2
Figure 2
ProMMP-1 concentration (A), MMP-1 activity (B), TIMP-1 concentration (C), proMMP-3 concentration (D), and MMP-3 activity (E) in synovial fluid of the study groups (values are medians with standard error bars). CTRL, knee-healthy controls; INFL, inflammatory arthritis (pseudogout); OA, osteoarthritis. α: pv INFL; ß: p<0.001, CTRL v OA.

References

    1. Ann Rheum Dis. 2002 Feb;61(2):161-6
    1. Arthritis Rheum. 2001 Oct;44(10):2263-74
    1. Arthritis Res. 2002;4 Suppl 3:S39-49
    1. J Rheumatol. 2002 Sep;29(9):1954-6
    1. FEBS Lett. 2002 Dec 4;532(1-2):127-30
    1. Arthritis Rheum. 2003 Aug;48(8):2178-87
    1. Ann Rheum Dis. 2003 Nov;62(11):1094-9
    1. Clin Exp Rheumatol. 2003 Nov-Dec;21(6):711-8
    1. Ann Rheum Dis. 2004 Jul;63(7):881-3
    1. Acta Orthop Scand Suppl. 1970;133:1-111
    1. J Bone Joint Surg Am. 1974 Jun;56(4):719-29
    1. Mol Cell Biochem. 1984;58(1-2):121-8
    1. Biochem Biophys Res Commun. 1985 Apr 30;128(2):795-802
    1. FEBS Lett. 1986 Dec 1;209(1):9-12
    1. Br J Rheumatol. 1987 Oct;26(5):354-8
    1. Ann N Y Acad Sci. 1999 Jun 30;878:388-403
    1. J Biol Chem. 1999 Jul 30;274(31):21491-4
    1. Clin Orthop Relat Res. 1988 Feb;227:229-37
    1. Matrix. 1990 Oct;10(5):285-91
    1. Arthritis Rheum. 1991 Sep;34(9):1139-50
    1. Arthritis Rheum. 1992 Jan;35(1):35-42
    1. Arthritis Rheum. 1993 Feb;36(2):181-9
    1. Arthritis Rheum. 1993 Sep;36(9):1214-22
    1. J Rheumatol. 1993 Aug;20(8):1362-8
    1. Ann Rheum Dis. 1994 Jan;53(1):8-13
    1. J Orthop Res. 1994 Jan;12(1):21-8
    1. Lab Invest. 1994 Jun;70(6):807-15
    1. Ann Rheum Dis. 1994 Dec;53(12):823-7
    1. Osteoarthritis Cartilage. 1995 Mar;3(1):7-14
    1. Ann Rheum Dis. 1995 Dec;54(12):970-5
    1. Clin Immunol Immunopathol. 1996 Feb;78(2):161-71
    1. FEBS Lett. 1996 Jul 22;390(2):221-5
    1. J Rheumatol. 1996 Sep;23(9):1599-604
    1. Ann Rheum Dis. 1996 Sep;55(9):622-6
    1. FEBS Lett. 1997 Dec 1;418(3):305-9
    1. J Invest Dermatol. 1998 May;110(5):771-6
    1. J Rheumatol. 1999 Jan;26(1):34-40
    1. Arthritis Rheum. 1999 Mar;42(3):534-44
    1. Ann Rheum Dis. 1999 Feb;58(2):109-13
    1. Ann Rheum Dis. 1999 Nov;58(11):691-7
    1. Biochim Biophys Acta. 2000 Mar 7;1477(1-2):267-83
    1. Ann Rheum Dis. 2000 Jun;59(6):455-61
    1. J Rheumatol. 2000 Dec;27(12):2761-8
    1. Exp Cell Res. 2001 Jun 10;266(2):303-10
    1. Rheumatology (Oxford). 2001 Jun;40(6):631-9
    1. Matrix Biol. 2002 Mar;21(2):185-95

Source: PubMed

3
Abonnere